Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ACT 1

Next Previous
Drug Profile

ACT 1

Alternative Names: ACT-1; alpha-Connexin carboxyl-Terminal 1 peptide - Xequel Bio; Granexin Gel; iNexin; αCT1

Latest Information Update: 28 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator FirstString Research; Medical University of South Carolina
  • Developer Medical University of South Carolina; Xequel Bio
  • Class Antineoplastics; Eye disorder therapies; Peptide fragments; Skin disorder therapies
  • Mechanism of Action Connexin 43 inhibitors; Zonula occludens protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Diabetic foot ulcer; Leg ulcer; Radiation injuries; Scars
  • Phase II/III Radiodermatitis
  • Phase II Burns; Corneal injuries
  • Phase I Dry eyes; Eye disorders
  • Preclinical Acute lung injury; Adult respiratory distress syndrome
  • No development reported Age-related macular degeneration; Corneal disorders; Fibrosis; Glioblastoma; Spinal cord injuries

Most Recent Events

  • 28 Jan 2024 No recent reports of development identified for preclinical development in Corneal-disorders in USA (Ophthalmic, Drops)
  • 10 Feb 2023 Phase-II clinical trials in Corneal injuries in USA (Ophthalmic) (Xequel Bio pipeline; February 2023)
  • 10 Feb 2023 Preclinical trials in Acute lung injury in USA (Inhalation) (Xequel Bio pipeline; February 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top